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AbstrACt
Objectives To estimate the potential impact of the 
addition of culture-based screening for group B 
streptococcus (GBS) carriage in pregnancy to a risk-
based prevention policy in the UK. We aimed to establish 
agreement within a multidisciplinary group of key 
stakeholders on the model input parameters.
Design Deterministic model using a consensus approach 
for the selection of input parameters.
setting and participants A theoretical annual cohort of 
711 999 live births in the UK (excluding births by elective 
caesarean section).
Interventions Culture-based screening for GBS at 35–37 
weeks of pregnancy added to the recommended risk-
based prevention policy in place on the date of modelling.
Outcome measures Outcomes assessed included use of 
intrapartum antibiotic prophylaxis (IAP), early onset GBS 
(EOGBS), EOGBS mortality, severe EOGBS-related morbidity 
and maternal penicillin anaphylaxis.
results With no prophylaxis strategy, the model estimated 
that there would be 421 cases of culture positive EOGBS in 
a year (0.59/1000 live births). In the risk-based prophylaxis 
scenario, 30 666 women were estimated to receive IAP 
and 70 cases of EOGBS were prevented. Addition of 
screening resulted in a further 96 260 women receiving 
IAP and the prevention of an additional 52 to 57 cases of 
EOGBS. This resulted in the prevention of three EOGBS 
deaths and four cases of severe disability. With screening, 
an additional 1675 to 1854 women receive IAP to prevent 
one EOGBS case and 24 065 to 32 087 receive IAP to 
prevent one EOGBS death.
Conclusions The evidence base available for a broad 
range of model input parameters was limited, leading 
to uncertainty in the estimates produced by the model. 
Where data was limited, the model input parameters were 
agreed with the multidisciplinary stakeholder group, the 
first time this has been done to our knowledge. The main 
impact of screening is likely to be on the large group of 
low-risk women where the clinical impact of EOGBS tends 
to be less severe. This model suggests that the reduction 
in mortality and severe disability due to EOGBS with 
antenatal GBS screening is likely to be very limited, with a 
high rate of overdetection and overuse of antibiotics.
IntrODuCtIOn
Group B Streptococcus (GBS) is a bacterium 
which can be commonly found in the diges-
tive system and female reproductive tract. It 
can be transmitted from a pregnant carrier 
to her newborn, typically during vaginal 
delivery.1 
While the bacterium does not usually cause 
harm, in some cases it can cause early onset 
infection in the newborn’s first week of life. 
This is termed early onset GBS (EOGBS) 
disease. In the UK, GBS is the most common 
cause of neonatal sepsis and meningitis.2 3
Comprehensive surveillance established an 
overall rate of EOGBS at 0.48 per 1000 live 
births in the UK and Ireland in 2000–2001.4 
Since then, routine laboratory surveillance 
has shown a fluctuation in incidence of 
culture positive EOGBS with slight increases 
between 2000 and 2010.5 Preliminary 
national surveillance data from 2014 to 2015 
suggests that the overall incidence of EOGBS 
was 0.57 per 1000 live births in the UK and 
Ireland.6 Clindamycin had been used as the 
main alternative to penicillin prophylaxis 
in women with penicillin allergy; however, 
since 2000 there has been a marked increase 
strengths and limitations of this study
 ► Model structure and input parameters were 
agreed  to by a multidisciplinary stakeholder group 
using a consensus building mechanism agreed to in 
advance.
 ► Deterministic one-way sensitivity analyses were 
carried out to assess the impact of changes to key 
model inputs.
 ► Systematic review to support each model input was 
not feasible; data sources were identified through 
broad systematic searches for recently published 
evidence. Higher quality evidence, such as sys-
tematic reviews, was used where available, as well 
as national sources including guidance and the UK 
National Screening Committee’s reviews.
 ► The modelling approach used was pragmatic and 
deterministic and so it does not provideCIs for mod-
el outputs.
 ► The evidence base available for many input param-
eters was limited and this leads to uncertainty in the 
model’s predictions.
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in resistance to clindamycin in patients of all ages.5 As a 
result, the most recent guidance from the Royal College 
of Obstetricians and Gynaecologists (RCOG), published 
in 2017, has recommended that clindamycin should no 
longer be used for this purpose.7 Vancomycin is now 
recommended by the RCOG as the antibiotic of choice 
for women with severe allergy to penicillin.
In the UK, the mortality rate in term newborns with 
EOGBS is estimated to be between 6% and 10.6%,4 8 
with a similar proportion left with severe morbidity.8 9 In 
pre-term newborns with EOGBS, the mortality rate is 
reported to be higher.10
Antenatal screening for Gbs
Pregnant women can be screened for GBS carriage in late 
pregnancy. Screening involves the collection of specimens 
using vaginal and rectal swabs which are processed using 
selective culture media.11 12 The purpose of screening is 
to identify a group of women who are eligible for intrave-
nous intrapartum antibiotic prophylaxis (IAP) as a means 
of preventing EOGBS disease.11 The mainstay of IAP is 
benzylpenicillin.
In the UK, currently there is agreement between the 
guidance issued by the UK National Screening Committee 
(UK NSC), the National Institute for Health and Care 
Excellence (NICE) and the RCOG that routine screening 
for GBS carriage should not be offered.6 7 13
A number of maternal risk factors for EOGBS have 
been identified. These include having a baby with GBS 
in a previous pregnancy, incidentally detected maternal 
GBS carriage, prematurity, prolonged membrane rupture 
and suspected infection in labour. In the UK, at the time 
of this modelling exercise (2014–2015), GBS IAP was 
recommended for women with either of the first two 
listed risk factors and broad spectrum antibiotics, with 
an agent active against GBS, recommended for women 
with suspected infection in labour.13 14 Since the comple-
tion of the modelling exercise, the RCOG has updated 
its guideline on GBS.7 The main change is that they now 
recommend offering GBS IAP to all women in confirmed 
pre-term labour. This is due to the increased risk of 
EOGBS and mortality in pre-term infants compared with 
term infants.
In 2017, the UK NSC completed the process of reviewing 
the evidence on antenatal GBS screening as part of its 
triennial review process.15 This review concluded that 
the recommendation not to implement screening in 
the UK should not be changed.6 This was because the 
committee considered there to be insufficient evidence 
on the balance of benefits and harms from culture-based 
screening and treating women with positive results with 
IAP.
The discussion on antenatal screening for GBS has 
taken place in a UK policy context shaped by the Mater-
nity Review,16National Health Service Outcomes Frame-
works17 and the Antimicrobial Resistance Strategy.18 
These major policy drivers emphasise issues ranging from 
patient choice and experience, place of birth, reduction 
of neonatal deaths, antibiotic stewardship and reduction 
of antibiotic usage. The potential impact of screening on 
these issues, therefore, needs to be considered.
The charity, Group B Strep Support (GBSS), has 
campaigned for screening since the 1990s. The contro-
versy surrounding the screening policy is reflected in 
journal debate,19–22 and politicians from the main parties 
in the four UK countries have signed petitions, raised 
parliamentary questions and led delegations on this issue. 
A petition in favour of screening, with over 250 000 signa-
tures, was delivered to the ministers and senior officials in 
January 2017.23
In part, this interest is stimulated by the implementa-
tion of antenatal screening for maternal GBS carriage 
in a number of developed countries. With few excep-
tions, retrospective cohort studies from these countries 
report a decline in the rate of culture positive EOGBS 
following the introduction of screening.24 For example, 
surveillance data from the USA reports reduced rates of 
EOGBS following implementation of each new policy 
change.11 The retrospective and observational design of 
these studies makes it difficult to ascertain if the data are 
complete, or if the reduction is conclusively attributable 
to screening alone.6 25
In addition, the absence of reports on the effect 
of screening on the rate of culture-negative sepsis 
presumed to be due to EOGBS disease limits interpre-
tation further.19 26 The difficulty in extrapolating data 
from different geographical settings has also been noted 
in relation to EOGBS.27However, the absence of suitably 
powered UK studies necessitates the use of available data 
from the UK and other countries, to estimate the poten-
tial impact of screening in the UK.
The UK NSC therefore convened a multidisciplinary, 
multi-agency expert group in 2014 to consider the avail-
able evidence to inform the development of a model to 
estimate the preventive potential of screening when added 
to current clinical practice. A pivotal aim of the process 
was to establish a shared set of assumptions among key 
stakeholders on a controversial topic.
MethODs
Model structure
A pragmatic deterministic model was developed in Micro-
soft Excel 2010 to simulate two scenarios in a 1-year 
UK pregnancy cohort. The first scenario was based on 
the risk-based management pathway recommended in 
the UK at the time of the model development (2014–
2015).13 14 The second scenario was the screening and 
risk-based scenario. In this scenario, antenatal culture-
based screening for GBS was offered at 36 weeks of preg-
nancy to women not already identified as being at risk 
through the risk-based strategy. This scenario was based 
broadly on the screening strategy recommended by the 
US Centers for Disease Control and Prevention 11 and the 
existing UK risk-based approach. This meant that women 
with known risk factors who should already be offered 
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IAP under UK guidelines continued to be offered IAP 
without screening. Women without these risk factors were 
offered screening. Women giving birth pre-term, before 
37 weeks, were assumed not to receive screening. This was 
due to the timing of the screening test at 36 weeks and 
the logistics of transport and laboratory processing time.
Within both scenarios, women were sequentially 
divided into mutually exclusive groups based on various 
clinical parameters.
In scenario one, the existing risk-based approach, the 
clinical characteristics on which the sequential divisions 
were based were as follows:
 ► Mode of birth (elective caesarean section or not).
 ► Presence of antenatal risk factors for EOGBS (a 
previous baby with EOGBS, incidental detection of 
GBS carriage or no risk factors).
 ► Timing of birth (term or pre-term).
 ► Presence of intrapartum risk factors for EOGBS 
(pre-term pre-labour rupture of membranes, 
suspected infection during labour, or ‘uncomplicated 
birth’, that is, no intrapartum risk factors).
This resulted in the population being divided into 15 
‘clinical risk groups’. These are depicted in figure 1.
In scenario 2, the screening and risk-based approach, 
women who had no antenatal risk factors for EOGBS and 
who gave birth at term were eligible for screening. The 
population eligible for screening is depicted in figure 2 
and was divided into groups based on:
 ► Receipt of screening (yes or no).
 ► Result of screening (positive or negative for GBS).
 ► GBS status at delivery (positive or negative for GBS).
 ► Presence of intrapartum risk factors for EOGBS 
(infection during labour or uncomplicated birth).
This resulted in 23 clinical risk groups in scenario two, 
comprising the 13 groups from scenario one which would 
not be eligible for screening plus an additional 10 groups 
resulting from screening. Risks for EOGBS and related 
outcomes had been agreed in advance and were applied 
to these groups to obtain the numbers of affected individ-
uals. The agreed risks are summarised in tables 1 and 2.
Figure 3 depicts the model structure for IAP and 
outcomes from the model.
To ensure a fair comparison, model outputs were 
checked to make sure that the number of EOGBS 
cases was equivalent in both scenarios if no antibiotic 
prophylaxis was given. In order to achieve this, the GBS 
Figure 1 Flow of the maternity cohort into antenatal and intrapartum risk factor groups. EOGBS, early onset GBS; IAP, 
intrapartum antibiotic prophylaxis; PROM, pre-labour rupture of membranes. 
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colonisation transition rates in the model needed to be 
adjusted to ensure that there was no overall change in 
GBS carriage rates between the time of screening and the 
time of delivery.
Consensus building approach
Members of the expert group are listed in table 3. They 
comprised representatives from UK organisations respon-
sible for the development of guidance, policy and patient 
advocacy relating to EOGBS, as well as experts with expe-
rience in clinical practice fields related to EOGBS, micro-
biology, epidemiology or statistics.
Members of the group were given the opportunity to 
comment on the structure of the model and individual 
model parameters.
Evidence identified in the UK NSC’s 2012 triennial 
review of antenatal GBS screening policy and national 
guidance documents were used to inform data used in 
the model.6 13 14 25 These were supplemented by a broad 
search in September 2014 for papers published since the 
2012 NSC evidence review (see online supplementary 
information for details). Relevant national data was also 
identified from sources such as the Office for National 
Statistics.
Higher quality evidence, such as systematic reviews28 29 
and randomised clinical trials, were prioritised as sources 
of data, as were studies from the UK.4 8 A summary of up 
to five potential values for each input parameter, based on 
the best available and most relevant evidence identified, 
was provided to the expert group. Where no evidence 
regarding an input parameter was identified , this was also 
noted.
Through a two part survey, the group was asked to 
consider the relevance of each input parameter, the most 
appropriate source of the parameter value, and the appli-
cability of the source-study findings to a UK population. 
Group members could also suggest alternative sources 
of data. In the absence of suitable published data for a 
parameter, the expert group selected a figure based on 
clinical experience and opinion.
All parameters and assumptions that received over 
70% agreement were included in the model unchanged. 
Those that did not meet this threshold were refined and 
resubmitted to the expert group. Those that received over 
50% agreement in the second round were included in the 
model. A small number of assumptions went forward to 
the second round. These focused on the details of the 
modelled IAP strategy. This included the timing and 
duration of IAP, whether second-line antibiotics should 
be included for analysis in the model, the schedule for 
those receiving IAP and subsequently developing fever in 
labour and whether IAP uptake and optimum duration 
should vary by risk group. All proposed changes received 
70% or more, except for one which received 65%.
The survey results informed two meetings of the expert 
group. The first meeting reviewed and agreed about the 
model structure and input parameters. The second 
received and discussed the outputs of the model.
Patient and public involvement
Representatives of GBSS were involved as members of 
the expert group in all stages of the group’s work. This 
included individual discussion with the project lead (DB) 
regarding the consensus building approach to agreeing 
to the model’s parameters, priorities and outcomes. It 
also included participation in the two-part survey and 
workshops to discuss the model.
Results of the model were disseminated to all 
members of the expert group in the form of a draft 
report of the modelling project. Comments received 
from GBSS raised a number of concerns about the 
outcomes of the model. These concerns centred on 
the emerging results of an enhanced surveillance study 
which suggested that the rate of EOGBS had increased 
Figure 2 Flow of screening eligible women through the screening scenario. Group B Streptococcus (GBS), intrapartum 
antibiotic prophylaxis (IAP) against early onset GBS (EOGBS).
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and that mortality had decreased.6 GBSS suggested 
that the model should be re-run with the new data and 
that greater emphasis on EOGBS in term women was 
needed. It was not possible to address all the concerns 
without reconvening the expert group in a new model-
ling exercise. However, GBSS’s concern prompted a 
post hoc analysis in term women with no risk factors 
indicating IAP. This is the most important group in the 
context of screening and the post hoc analysis is briefly 
reported later in this paper.
Outcomes
Outcomes for each scenario were evaluated in a hypo-
thetical UK maternity cohort, over a 1-year period. 
The outcomes were total culture positive EOGBS 
infections, EOGBS mortality and severe morbidity 
(eg, severe motor, intellectual, visual, hearing or other 
neurological impairment that meant the child was not 
able to attend mainstream school), use of IAP and 
maternal penicillin anaphylaxis. These outcomes were 
combined to explore the number of additional women 
needed to be treated with IAP to prevent additional 
EOGBS cases, deaths and severe disability.
The expert group noted that some of the model input 
parameters were based on low quality or inconclusive 
evidence. In order to explore the effect these data may 
have on outcomes, one-way sensitivity analyses were 
Table 1 Population characteristics and early onset GBS (EOGBS) mortality and morbidity outcomes
Parameter Input data Data source
Maternity population characteristics
  Number of live births* England and Wales – 718 235
Scotland – 57 202
Northern Ireland – 24 890
Total – 800 327
Office for National Statistics 2012 live birth data38
Information Services Division Scotland 2012–
2013 data39 and National Records of Scotland 
2012 data40
Northern Ireland Statistics and Research Agency 
201241
  Elective caesarean section rate England – 10.7%
Wales – 11.7%
Scotland – 12.8%
Northern Ireland – 15.3%
Total −11.04%*
Hospital Episode Statistics (HES) 2012–2013 
data42
Stats Wales 2012–2013 data43
ISD Scotland 2012-2013 data39
Department of Health, Social Services and Public 
Safety Northern Ireland 2012–2013 data41
  Pre-term birth rate 8.2% HES 2012–2013 data42
Risk factors indicating intrapartum antibiotics in UK guidance
Proportion of the population with antenatal risk factors for EOGBS
  Previous infant with EOGBS 0.03% of model cohort Colbourn et al, 20079
  Incidental group B S treptococcus 
detection
5.0% of model cohort Expert group consensus agreement based on 
Colbourn et al, 20079 and Daniels et al, 2011 44
Proportion of the term population with intrapartum risk factors
  Rate of maternal intrapartum infection 
in term deliveries
2.1% Daniels et al, 201144
Proportion of the pre-term population with additional intrapartum risk factors
  Rate of maternal intrapartum infection 
in pre-term deliveries
4.1% Daniels et al, 201144
  Rate of pre-labour rupture of 
membranes (PROM) in pre-term 
deliveries
40% Royal College of Obstetricians and 
Gynaecologists (RCOG) Pre-term PROM Green-
top guideline 44, 201045
EOGBS mortality and morbidity outcomes
  Mortality in pre-term babies with 
EOGBS
18.3% RCOG, 201214 [derived from Heath et al, 20044]
  Mortality in term babies with EOGBS 5.7% RCOG, 201214 [derived from Heath et al, 20044]
  Morbidity in pre-term babies with 
EOGBS
6.91% Expert group consensus agreement [based on 
Colbourn et al, 20079]
  Morbidity in term babies with EOGBS 6.89% Expert group consensus agreement [based on 
Colbourn et al., 20079]
*Excludes stillbirths, miscarriages and terminations; multiple births are only counted once.
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carried out to look at the impact of varying the following 
input parameters:
 ► Screening uptake rate.
 ► Antibiotic delivery in screen positive women.
 ► Effectiveness of IAP in preventing EOGBS.
 ► Transition rates for GBS status from screening to 
delivery.
The sensitivity analyses were run using a plausible 
lower and higher estimate, based on ranges agreed by the 
expert group. Individual parameters were changed one at 
a time, leaving all other parameters unchanged to provide 
discrete analyses of their impact. Input parameter values 
and data sources are presented in tables 1, 2, 4 and 5.
results
The model’s key results are presented in table 6.
Based on the inputs 800 327 live births were included in 
the model. Current guidance recommends that women 
with intact membranes undergoing elective caesarean 
should not receive GBS IAP in the absence of labour.14 
As such, live births by elective caesarean were excluded, 
reducing the number included in the analysis to 711 999. 
Without IAP, there were an estimated 421 cases of culture 
positive EOGBS, a rate of 0.59/1000 live births. The 
modelled estimate of deaths and severe disability caused 
by EOGBS without IAP was 42 and 29 respectively.
In the risk based scenario, 30 666 women were esti-
mated to receive antibiotics in labour and 70 cases of 
EOGBS prevented. In the screening scenario, a further 
96 260 women received IAP on the basis of the screening 
result. This resulted in the prevention of an additional 52 
to 57 cases of EOGBS (range in sensitivity analyses: 40 to 
67) which included the prevention of three deaths (range 
in sensitivity analyses: two to four) and four cases of severe 
disability (range in sensitivity analyses: 3 to 5). This means 
that with screening, an additional 1675 to 1854 women 
receive IAP to prevent one EOGBS case and 24 065 to 
32 087, to prevent one EOGBS death. Maternal anaphy-
laxis remained an extremely rare event in both scenarios, 
with 0.3 cases in the risk based scenario and 1.7 cases in 
the screening scenario.
Among women receiving IAP in the model, 8% 
received clindamycin due to reported penicillin allergy. 
It was assumed that treatment failure due to clindamycin 
resistance would be avoided by susceptibility testing in 
screen-positive women.
The sensitivity analyses did not have a large impact on 
results (see ranges above). An additional, post hoc anal-
ysis, focusing on term women with no risk factors indi-
cating IAP, was undertaken. All parameters remained the 
same as those described above. However, an increase in 
Table 2 Estimated early onset GBS (EOGBS) incidence rates in each clinical risk group
Risk group Input data Data source
Background incidence/risk group
  No risk factors at term 0.2 per 1000 births Royal College of Obstetricians and 
Gynaecologists (RCOG), 201214
  Suspected maternal infection at term 5.29 per 1000 births RCOG, 201214
  Pre-term birth 2.30 per 1000 births RCOG, 201214
  Suspected maternal infection at pre-term 5.29 per 1000 births Expert group consensus agreement 
based on RCOG, 201214
  Pre-term pre-labour rupture of membranes 2.30 per 1000 births Expert group consensus agreement 
based on RCOG, 201214
  Previous baby with EOGBS with no other risk factors 50 per 1000 births Expert group consensus agreement
Incidence rate/1000 births
  Previous baby with EOGBS with one more additional 
risk factor
100 per 1000 births Expert group consensus agreement
  Incidental group B Streptococcus detection 2.30 per 1000 births Expert group consensus agreement 
based on RCOG, 201214
  GBS carrier in labour with no other antenatal or 
intrapartum risk factors, delivering at term
0.91 per 1000 births Expert group consensus agreement 
based on available data
  GBS carrier in labour with suspected maternal 
infection, delivering at term
24.0 per 1000 births Expert group consensus agreement 
based on available data
  Not a GBS carrier in labour, delivering at term (with or 
without suspected maternal infection)
0 per 1000 births Expert group consensus agreement
Background colonisation rate
  Colonisation rate 22%
[Sensitivity analysis: 
20%–30%]
Expert group consensus agreement
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the rate of EOGBS in carriers in this group along with 
a decrease in mortality was assumed. When the rate of 
EOGBS was double that used in the model, the additional 
number of women receiving IAP to prevent a case of 
EOGBS was 844 to 926. The reduced mortality rate meant 
that the number of women receiving IAP to prevent a 
death from EOGBS remained the same as the model’s 
main estimate of 24 065 to 32 087.
DIsCussIOn
The key outcomes of the model are summarised in box 1.
This model suggests that the additional reduction in 
mortality and severe disability due to EOGBS with culture-
based screening for maternal GBS carriage added to the 
current risk-based approach is likely to be, numerically, 
very limited in the UK . The addition of screening to the 
modelled risk-based prevention strategy increased the 
prevention of EOGBS cases from approximately 16% with 
the risk-based prevention strategy alone to approximately 
25% of the modelled total. Similarly, the proportion of 
deaths prevented increased from approximately 12% to 
19%.
There are a number of reasons for this limited numer-
ical impact. The distribution of EOGBS across the risk 
groups and the clustering of its worst effects in groups 
outside the screening population limit the benefits that 
can be expected. In the model, 54% of the EOGBS cases 
and 75% of deaths occurred in groups which were not 
eligible for screening, notably in the groups of women 
who already have known risk factors for EOGBS prior to 
36 weeks or who give birth pre-term. In addition, not all 
women carrying GBS at labour would be correctly identi-
fied by the test. The model estimated that between 20 916 
and 30 726 women who screened negative at 36 weeks 
gestation would be GBS positive at delivery. This group 
comprised women whose GBS carriage status was esti-
mated to change from negative at the point of screening 
to positive at the time of labour. This number includes 
women truly transitioning in carriage status and also 
those receiving false negative screening test results.
Expert consensus and examples of non-UK based 
screening programmes suggest that attrition along the 
pathway should be expected and that uptake of both 
screening and IAP would be less than 100%. In addition, 
the delivery of IAP for sub-optimum durations is thought 
to reduce its prophylactic effect and was factored into 
the model. However, it should be noted that estimates 
of effectiveness are not well grounded in clinical trial 
evidence,29 and the evidence base exploring duration of 
administration and prophylactic effect is limited to obser-
vational studies.30–32
Prevention of EOGBS as a result of screening has to be 
considered in relation to the impact on the population 
as a whole. The likelihood of having a baby affected by 
Figure 3 Model structure for women with an indication for intrapartum antibiotic prophylaxis (IAP) and outcomes of babies 
with early onset GBS (EOGBS).
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EOGBS appears to be low in women delivering at term 
with no known risk factors; a rate of about 0.2/1,000 
live births was used in the model. These are the women 
who would be eligible for screening. Studies of ante-
natal GBS screening test accuracy mainly focus on accu-
racy for predicting maternal GBS carriage at delivery, 
and rarely report on neonatal outcomes or ability of the 
test to predict these.6 28 The positive predictive value of 
screening in late pregnancy for the outcome of EOGBS 
has recently been estimated as approximately 0.2% (2 
cases of EOGBS per 1000 screen-detected carriers).6 This 
would be the level of risk reported to women who screen 
positive. Overdetection is a constant concern about 
screening, and its high rate in this context means that the 
ability of GBS screening to provide high quality post-test 
information may need to be questioned.
Overtreatment is a consequence of overdetection. A 
number of factors contribute to the high rate of overuse 
of IAP as a consequence of screening. The model esti-
mated that between 16 382 and 24 065 screen positive 
women would receive antibiotics when they are no longer 
carrying the bacterium during labour. In addition, a large 
proportion of carriers in labour do not transmit the bacte-
rium to the neonate during delivery.6 33 Among colonised 
neonates, only 3% develop EOGBS.34
The absence of a diagnostic or risk refinement 
strategy, to follow a screen-positive result means that 
many thousands of women would receive GBS IAP 
to manage a very low risk of EOGBS affecting their 
baby.
Reports of GBS organisms with reduced susceptibility, 
or resistance to penicillin, have caused concern despite 
being very rare and of uncertain clinical significance.5 11 
While clindamycin has previously been recommended 
for IAP in women with penicillin allergy, the increase 
in resistance to this antibiotic has led to RCOG recom-
mending that it should no longer be used for this 
purpose.7 In addition to this, the possibility has been 
raised that intrapartum antibiotics may have long-term 
effects on the infant gut flora and research into this is 
in the early stages.6
The difficulty in quantifying the harm of GBS IAP may 
make screening appear to be a harm-free intervention.6 
However, the use of antibiotics in such a large group of 
women, the vast majority of whom will not experience 
benefit, means its fit with the current policy emphasis 
on prudent antibiotic prescribing goals18 may be diffi-
cult. This is because, as modelled, screening would 
do little to reduce antibiotic usage in the clinical risk 
groups who already receive IAP, there is low risk of 
EOGBS in the screened population, limited impact of 
screening on the worst outcomes, a lack of evidence to 
estimate whether outcomes are different for screen-de-
tected and clinically-detected babies with EOGBS and 
Table 3 Members of the expert group
Expert group member Position
Professor Catherine Peckham 
(Chair)
National Health Service (NHS), NHS Infectious Diseases in Pregnancy Screening Programme, Executive 
Lead/Institute for Child Health
Dr Alison Bedford-Russell Neonatologist, Birmingham Women’s Hospital/Group B Strep Support (GBSS)
Professor Peter Brocklehurst Director, Birmingham Clinical Trials Unit, University of Birmingham/Royal College of Obstetricians and 
Gynaecologists (RCOG) Greentop Guideline
Professor Androulla Efstratiou Head, WHO Global Reference Centre for Diphtheria & Streptococcal Infections and European Centre for 
Disease Prevention and Control, UK Scientific Coordinator
Professor Paul Heath Consultant in paediatric infectious diseases, St George’s University of London & St Georges University 
Hospitals NHS Trust, London: BPSU study/RCOG Greentop Guideline
Dr Rhona Hughes Obstetrician, Edinburgh/RCOG Greentop Guideline
Dr Theresa Lamagni Senior Epidemiologist and Section Head,
Healthcare-Associated Infection & Antimicrobial Resistance Division, National Infection Service, Public 
Health England (PHE)
Dr Anne Mackie Director of Screening & Screening Quality Assurance, PHE
Mr John Marshall Evidence Lead, UK National Screening Committee
Dr Rachel Moll National Medical Director’s Fellow, PHE
Mrs Jane Plumb Chief Executive,GBSS
Dr Julie Robotham Statistics, Modelling and Economics Department, PHE
Ms Farah Seedat PhD student, University of Warwick
Dr Nan Shetty Consultant Microbiologist and Training Lead, Reference Microbiology Services,
PHE
Professor Helen Spiby Professor of Midwifery, University of Nottingham
Professor Phillip Steer Emeritus Professor of Obstetrics & Gynaecology, Imperial College/GBSS
Professor Ben Stenson Neonatologist, Royal Infirmary of Edinburgh/RCOG Greentop Guideline
Professor Mark Turner Neonatologist, Liverpool Women’s NHS Foundation Trust
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a high rate of overtreatment. In addition, the large 
number of additional women receiving GBS IAP will 
need to do so in a setting where the antibiotics can be 
delivered intravenously. This may reduce the choice of 
birth setting for these women by removing the option of 
home birth.
Table 4 Antibiotic uptake, optimal and suboptimal delivery, anaphylaxis
Parameter Input data Data source
Uptake of antibiotics
  Maternal infection at term 80% Expert group consensus agreement
  Maternal infection at pre-
term
85% Expert group consensus agreement
  Pre-term pre-labour rupture 
of membranes (pPROM) 
5% Expert group consensus agreement
  Screened group B 
Streptococcus (GBS) 
positive
80% [Sensitivity analysis 
70%–90%]
Expert group consensus agreement [based on Albouy-Llaty et 
al. 201246]
  Previous baby with early 
onset GBS (EOGBS)
90% Expert group consensus agreement
  Incidental detection of GBS 
carriage
47% Moorthy et al, 201447




Optimal IAP (delivered 
>2 hours)
Suboptimal IAP (delivered 
<2 hours) Data source
Groups treated with antibiotics 
not solely for prevention of 
EOGBS
  Maternal infection at term 20% 80% Expert group consensus 
agreement
  Maternal infection at pre-
term
10% 90% Expert group consensus 
agreement
  pPROM 65% 35% Expert group consensus 
agreement
Groups receiving IAP solely for the prevention of EOGBS
  Screened GBS positive 65% 35% Expert group consensus 
agreement [based on Lin et al., 
201130]
  Previous baby with EOGBS 65% 35% Expert group consensus 
agreement
  Incidental detection of GBS 
carriage
65% 35% Expert group consensus 
agreement
IAP effectiveness in preventing EOGBS
  IAP effectiveness (prevention 
of EOGBS)
RR* 0.17 (Sensitivity analysis 
0.05 to 0.30)
RR=relative risk
RR* 0.58 (Sensitivity analysis 
0.525 to 0.65)
Suboptimal effectiveness is 
50% lower than optimal
Ohlsson et al, 201429 (optimal) 
and expert group consensus 
agreement (sub-optimal)
Allergy, resistance and anaphylaxis rates
  Self-reported penicillin 
allergy rate
8% Turrentine et al, 200948 and 
Zilberman et al, 201449
  Clindamycin resistance rate 17% Public Health England , 2014 
(2013 data)50
  Maternal penicillin 
anaphylaxis
1.56 per 100 000 women treated Mulla et al, 201051
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strengths and limitations
Antenatal screening for GBS is a controversial topic, 
and one of the strengths of this study was the use of a 
multidisciplinary stakeholder group encompassing a 
wide range of viewpoints, to gain consensus on the model 
structure and inputs. To our knowledge, this is the first 
Table 5 Screening test uptake and colonisation status transitions between screening and delivery
Screening uptake
Parameter Input data Data source
Screening uptake rate 90%
[Sensitivity analysis – 75%–95%]
Expert group consensus agreement
Colonisation status transition
‘Transition rate’ from group B 
Streptococcus (GBS+) at 36 weeks to 
GBS- at delivery*
Base case 1: 25%
Base case 2: 17%
[Sensitivity analysis 11.7%–40%]
Valkenburg-van den Berg et al. 2010,28 
Di Renzo et al 201552 and expert group 
consensus agreement
‘Transition rate’ from GBS- at 36 weeks to 
GBS+ at delivery*
Base case 1: 7.1%
Base case 2: 4.8%
[Sensitivity analysis 3.3%–12%]
Valkenburg-van den Berg et al. 2010,28 
Di Renzo et al 201552 and expert group 
consensus agreement
*NB: Based on the data available, it is not possible to distinguish between women who have an incorrect screening result (ie, false positive or 
false negative) and whose true colonisation status remains unchanged at delivery, and those who had a correct screening result (true positive 
or true negative) and then transition to a different colonisation status at delivery.
Table 6 Model results
Risk group
Outcomes before 
application of either 
prevention scenario 
(baseline)
Scenario 1 (risk-based 
prevention)




















Neonate affected by EOGBS in a 
previous pregnancy
214 12 IAP and broad 
spectrum*
192 IAP and broad spectrum* 192
Incidental detection of maternal GBS 
carriage
35 600 84 IAP and broad 
spectrum*
17 005 IAP and broad spectrum* 17 005
Pre-term delivery without the above risk 
factors
55 446 134 Broad 
spectrum*
3041 Broad spectrum* 3041
Suspected intrapartum infection at term 
without the above risk factors
13 036 69 Broad 
spectrum*
10 428 Broad spectrum* in all, 
preceded by IAP in
2065 screen-positive women
10 428
Term women with no antenatal or 
intrapartum risk factors indicating 
intrapartum antibiotic prophylaxis (IAP) 
(without screening)
607 703 122 N/A 0 IAP for women who screen 
group B Streptococcus GBS 
positive
96 260
Summary Baseline Scenario 1 Scenario 2




30 666 Treated with antibiotics 126 926
EOGBS 
cases
421 EOGBS cases 
prevented
70 EOGBS cases prevented 122–127
Deaths from 
EOGBS
42 Deaths from 
EOGBS 
prevented










5 Severe disability from EOGBS 
prevented
8–9
*Broad spectrum antibiotics given to those with suspected intrapartum infection.
N/A, not applicable.
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time this approach has been taken to inform a model of 
antenatal GBS screening.
Data sources were identified through the use of UK 
National Screening Committee evidence reviews and 
broad systematic searches for subsequently published 
evidence. Higher quality evidence, such as published 
systematic reviews were used where available, as well as 
national sources including guidance and national statis-
tics. However, systematic reviews to support each model 
input were not feasible. In addition, the expert group 
provided input on realistic input values in the absence of 
relevant evidence.
Limited evidence was available for many model param-
eters. This includes the rate of penicillin anaphylaxis and 
the proportion of pregnant women reporting allergy to 
penicillin. Research to inform these and other inputs 
would improve future modelling exercises. Research 
into factors which impact EOGBS risk in babies born to 
women colonised by GBS could be valuable in the devel-
opment of a post-screening risk refinement strategy to 
narrow the pool of women receiving antibiotics.
There is uncertainty regarding the model’s outputs due 
to limitations in the underlying evidence. The results are 
not dissimilar to those estimated by a hospital in Australia 
which introduced universal screening. Planned and 
post hoc sensitivity analyses did not substantially affect 
this. This Australian study estimated that 1190 women 
received IAP to prevent one case of EOGBS.35 However, it 
was not clear whether their figure took into account the 
women who would have received IAP based on the risk-
based approach prior to the introduction of screening. In 
addition, the study was observational and the number of 
births during the screening period relatively small; so the 
estimate of EOGBS cases prevented may not have been 
very robust.
Since the completion of the modelling exercise, there 
have been changes to the UK’s recommended risk-based 
strategy, mainly that the RCOG has now recommend 
offering IAP to all women in established pre-term labour. 
No analysis was undertaken to estimate the effect of these 
changes. However, this change should not influence the 
screening scenario, as women who give birth pre-term 
would not have had the chance to be screened.
The model focused on a limited set of outcomes. In 
part, this related to the overall aims of the project, which 
was to try to establish a set of shared assumptions about 
a core set of basic parameters and outcomes. However, it 
was also related to the limitations in the data available; 
for example, it was not considered possible within the 
terms of this project to model outcomes relating to mild 
or moderate disability arising from EOGBS.
The model did not explore qualitative questions, for 
example whether screening would affect maternal choice, 
the medicalisation of labour or women’s experience of 
maternity services.
COnClusIOn
This is the first time a consensus-based assessment of the 
evidence has been developed within a UK-based expert 
group. A very limited evidence base was encountered 
and important issues such as the impact of screening 
on culture-negative disease or on women’s birth expe-
rience could not be addressed. However, consensus was 
achieved on the structure of the model and the parame-
ters required for an estimate of the preventive potential 
of screening.
The resulting outputs focus attention on a hypothetical 
screening programme which was estimated to combine 
a low impact, in terms of preventing the worst aspects of 
EOGBS, with a high impact, in terms of the volume of 
women categorised as high risk and treated with prophy-
lactic antibiotics in labour.
Expectations about the benefits of interventions, 
including screening interventions, can be overestimated 
by both patients and health professionals.36 37 The model-
ling work steered by this expert group provides a useful 
sense of perspective on antenatal screening for maternal 
GBS carriage.
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